Bifunctional protein, preparation and use

Details Bifunctional protein, preparation and use Bifunctional protein, preparation and use

2006-01-10

2006-01-10

Canella, Karen A. (Department: 1642)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Animal or plant cell

C435S069600, C435S069700, C435S070100, C435S328000, C435S330000, C435S344000, C435S372300, C435S069100, C536S023400, C536S023530

Reexamination Certificate

active

06984382

ABSTRACT:
A bifunctional protein comprising: 1) a single-chain antibody directed against a suitable antigen on a tumour cell, 2) a hinge region comprising from about 40 to about 200 amino acids joined to the VLdomain of the single chain antibody, and 3) a functional zeta (ζ) chain from the T-cell antigen receptor (TCR) joined to the hinge region, wherein the hinge region is an immunoglobin-like hinge region which is joined to the C-terminus of the VLdomain of the single-chain antibody. The functional zeta (ζ) chain comprises the transmembrane and the cytoplasmic domain. The bifunctional protein can be expressed using a cytotoxic lymphocyte (CTL) expressing DNA encoding it.

REFERENCES:
patent: 5571894 (1996-11-01), Wels et al.
patent: 5939531 (1999-08-01), Wels et al.
patent: 0260880 (1988-03-01), None
patent: 0336379 (1989-10-01), None
patent: 0499555 (1992-08-01), None
patent: 0 502 812 (1992-09-01), None
patent: 0502812 (1992-09-01), None
patent: 0565794 (1993-10-01), None
patent: 8906692 (1989-07-01), None
patent: 9207943 (1992-05-01), None
patent: 9210591 (1992-06-01), None
patent: 9215322 (1992-09-01), None
patent: 9215326 (1992-09-01), None
patent: 9319163 (1993-09-01), None
patent: WO 95/30014 (1995-11-01), None
Stancovski et al, “Targeting T Lymphocytes to Neu/Her2-expressing Cells Using Chimeric Single Chain Fv Receptors”, The Journal of Immunology, 1993, vol. 151, pp. 6577-6582.
Horgan et al, “Studies on the antigen binding by intact and hinge-deleted chimeric antibodies”, Journal of Immunology, 1993, vol. 150, pp. 5400-5407. (abstract).
Huse et al (Science, 1989, vol. 246, pp. 1275-1281).
Verma et al (Nature, 1997, vol. 389, pp. 239-242).
Eck et al (Gene-Based Therapy, In: The Pharmacological Basis of Therapeutics, Goodman and Gilman, Ed.s, 1996, pp. 77-101).
Orkin et al ( “Report and Recommendation of the Panel to Assess the NIH Investment in Research on Gene Therapy”, NIH, 1995).
Clark (Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man, 1993, p. 1).
Abraham, et al., TIBS, vol. 17, 1992, pp. 434-438.
Baniyash, et al., J. Bio. Chem., vol. 263, No. 20, 1988, pp. 9874-9878.
Boon, Advances in Cancer Research, vol. 58, 1992, pp. 177-210.
Brocker, et al., Eur. J. Immunol., vol. 23, 1993, pp. 1435-1439.
Classon, et al., Int'l Immunol., vol. 4, 1992, No. 2, pp. 215-225.
Diamond, et al., J. Exp. Med., vol. 174, 1991, pp. 229-241.
Dohlsten, et al., PNAS (USA), vol. 88, 1991, pp. 9287-9291.
Eichmann, et al., J. Immunol., vol. 147, No. 7, 1991, pp. 2075-2081.
Eshhar, et al., J. Cell. Biochem., Suppl. 14B, 1990, pp. CE 112.
Eshhar, et al., PNAS (USA), vol. 90, 1993, pp. 720-724.
Frank, et al., Science, vol. 249, 1990, pp. 174-177.
Gross, et al., The FASEB Journal, vol. 6, 1992, pp. 3370-3378.
Hwu, et al., J. Exp. Med., vol. 178, 1993, pp. 361-366.
Hwu, et al., J. Immunol., vol. 150, No. 9, 1993, pp. 4104-4115.
Jin, et al., PNAS (USA), vol. 87, 1990, pp. 3319-3323.
Karasuyama, et al., Eur. J. Immunol., vol. 18, 1988, pp. 97-104.
Kast, et al., Cell, vol. 59, 1989, pp. 603-614.
Letoumeur, et al., PNAS (USA), vol. 88, 1991, pp. 8905-8909.
Lopez, et al., Cytometry, vol. 10, 1989, pp. 165-173.
Miller, et al., Bio/Techniques, vol. 7, No. 9, 1989, pp. 980-986.
Morgenstern, et al., Nuc. Acids Res., vol. 18, No. 12, 1990, pp. 3587-3596.
Moritz, et al., Gene Therapy, vol. 2, 1995, pp. 539-546.
Moritz, et al., PNAS (USA), vol. 91, 1994, pp. 4318-4322.
Orloff, et al., Nature, vol. 347, 1990, pp. 189-191.
Orloff, et al., J. Bio. Chem., vol. 264, No. 25, 1989, pp. 14812-14817.
Riddell, et al., Science, vol. 257, 1992, pp. 238-240.
Romeo, et al., Cell, vol. 64, 1991, pp. 1037-1046.
Schlichtholz, et al., Cancer Research, vol. 52, 1992, pp. 6380-6384.
Shalaby, et al., J. Exp. Med., vol. 175, 1992, pp. 217-225.
Stancovski, et al., J. Immunol., vol. 151, 1993, pp. 6577-6582.
Weiss, Cell, vol. 73, Apr. 23, 1993, pp. 209-212.
Weissman, et al., PNAS (USA), vol. 85, 1988, pp. 9709-9713.
Weissman, et al., Science, vol. 239, 1988, pp. 1018-1021.
Wels, et al., Bio/Technology, vol. 10, 1992, pp. 1128-1132.
Winn, J. Immunol., vol. 86, No. 1, 1961, pp. 228-235.
Zamoyska, et al., Cell, vol. 43, 1985, pp. 153-163.
Meulenbroek, A.J. and Zeijlemaker, W.P., Human IgG Subclasses: Useful diagnostic markers for Immunocompetence (CLB 1996); <http://www.xs4all.nl/-ednieuw/IgGsubclasses/subkl23.htm>.

Affiliated with

Also associated with

Rating

Bifunctional protein, preparation and use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Bifunctional protein, preparation and use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bifunctional protein, preparation and use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3603506